An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia

Trial Profile

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Sucroferric oxyhydroxide (Primary) ; Calcium acetate
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vifor Fresenius Medical Care Renal Pharma
  • Most Recent Events

    • 27 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2019.
    • 23 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 25 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top